|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||
| Investments, at fair value | |||||||||||||||||
| Non-controlled/unaffiliated | |||||||||||||||||
| Non-controlled/affiliated | |||||||||||||||||
| Controlled/affiliated | |||||||||||||||||
| Total investments, at fair value | |||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||
| Money Market Funds | |||||||||||||||||
| Total cash and cash equivalents | |||||||||||||||||
| Restricted cash | |||||||||||||||||
| Foreign currency, at fair value (cost—$9 and $27, respectively) | |||||||||||||||||
| Receivable for investments sold and repaid | |||||||||||||||||
| Income receivable | |||||||||||||||||
| Unrealized appreciation on foreign currency forward contracts | |||||||||||||||||
| Deferred financing costs | |||||||||||||||||
| Prepaid expenses and other assets | |||||||||||||||||
| Total assets | |||||||||||||||||
| Liabilities | |||||||||||||||||
| Payable for investments purchased | |||||||||||||||||
| Debt (net of deferred financing costs and discount of $46 and $45, respectively) | |||||||||||||||||
| Unrealized depreciation on foreign currency forward contracts | |||||||||||||||||
| Stockholder distributions payable | |||||||||||||||||
| Management fees payable | |||||||||||||||||
| Subordinated income incentive fees payable | |||||||||||||||||
| Administrative services expense payable | |||||||||||||||||
| Interest payable | |||||||||||||||||
| Other accrued expenses and liabilities | |||||||||||||||||
| Total liabilities | |||||||||||||||||
| Preferred stock, $0.001 par value per share, 50,000,000 shares authorized, respectively; 6,000,000 and 0 Cumulative Convertible Perpetual Preferred Stock, Series A shares, $0.001 par value per share, $25.00 liquidation preference per share, issued and outstanding, respectively | |||||||||||||||||
| Stockholders’ equity | |||||||||||||||||
| Preferred stock, $0.001 par value, 50,000,000 shares authorized, none issued and outstanding | |||||||||||||||||
| Common stock, $0.001 par value per share, 750,000,000 shares authorized, respectively, 273,532,761 and 280,066,433 shares issued and outstanding, respectively | |||||||||||||||||
| Capital in excess of par value | |||||||||||||||||
| Retained earnings (accumulated deficit) | |||||||||||||||||
| Total stockholders’ equity | |||||||||||||||||
| Total liabilities, preferred stock and stockholders’ equity | |||||||||||||||||
| Net asset value per share of common stock at period end (in dollars per share) |
Loading...